

Emapalumab

Care Team Contact Information: _____

Pharmacy Contact Information: _____

Diagnosis: _____

- This treatment is used for:
 - A rare immune disorder called primary hemophagocytic lymphohistiocytosis (HLH)
 - HLH with macrophage activation syndrome (MAS) in Still's disease
- It may also be used for other reasons.

Goal of Treatment: _____

- Treatment may continue for a certain time period or until side effects are no longer controlled.

Treatment Regimen

Treatment Name	How the Treatment Works	How the Treatment is Given
Emapalumab (EH-muh-PAL-yoo-mab): Gamifant (GA-mih-fant)	Blocks a protein in the immune system that causes inflammation.	Infusion into a vein (intravenous (IV) infusion).

Treatment Administration and Schedule

Treatment is typically repeated every 3 to 4 days.

☐ Option 1: Primary HLH and HLH with MAS

- Emapalumab is given every 3 days.

Treatment Name	Week 1							Next Week		
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 1	Day 2	Day 3
Emapalumab	✓			✓			✓			✓

☐ Option 2: Primary HLH

- Emapalumab is given every 4 days.

Treatment Name	Week 1							Next Week	
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 1	Day 2
Emapalumab	✓				✓				✓

Option 3: HLH with MAS

- Emapalumab is given on Day 1, then every 3 days on Days 4 to 16, then every 4 days.

Treatment Name	Treatment Schedule																				
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9	Day 10	Day 11	Day 12	Day 13	Day 14	Day 15	Day 16	Day 17	Day 18	Day 19	Day 20	...
Emapalumab	✓			✓			✓			✓			✓			✓				✓	

Appointments

Appointments may include regular check-ups with your care team, treatment appointments, lab visits, and imaging tests. It's important to keep your appointments whenever you can. If you miss an appointment, call your care team as soon as possible to reschedule it.

Supportive Care to Prevent and Treat Side Effects

Description	Supportive Care Given at the Clinic or Hospital	Supportive Care Taken at Home
To help lower the risk of infections		
Other		

Common Side Effects

Side Effect	Important Information
Infections	Description: Treatment may increase your chance of getting an infection. Your care team may perform a test before you start treatment to rule out tuberculosis (TB). Recommendations: - Wash your hands often and bathe regularly. - Avoid crowded places and close contact with people who are sick. - Keep any catheter/port site clean and dry. Follow all instructions provided by your care team. Talk to your care team if you have: - Fever of 100.4°F (38°C) or higher - Chills - New or worsening cough or sore throat - Painful urination or signs of a urinary infection - Feeling much more tired than usual - Red, swollen, warm, or painful areas on the skin (possible skin infection)

High Blood Pressure (Hypertension)	Description: High blood pressure means the force of blood against your artery walls is too high. Treatment can raise your blood pressure or make it harder to control. Recommendations: - Exercise regularly, maintain a healthy weight, and limit alcohol and salt (sodium). - Take blood pressure medicines as prescribed. Your care team may change your medicines if needed. - Your care team may ask you to check and record your blood pressure at home. Bring readings to appointments. - Follow diet and lifestyle advice from your care team. Talk to your care team if you have: - Severe or new headaches - Dizziness or lightheadedness - Blurred vision - Trouble breathing - Nosebleeds that do not stop - A pounding sensation in your chest, neck, or ears - Irregular or fast heartbeats - Chest pain or pressure
Infusion-Related Reactions	Description: An infusion reaction is a bad response that can happen during or shortly after receiving medicine through a vein. Recommendations: - Your care team may prescribe medicines before your infusion to help reduce your risk of infusion reactions or make any infusion reaction less severe. - You may be monitored for infusion reactions during each infusion. - Your care team may slow down or stop your infusion, or completely stop treatment if you have an infusion reaction. Get medical help right away if you develop any of the following during or after your infusion: - Chills or shaking - Itching, rash, or flushing - Trouble breathing, wheezing, or tongue swelling - Dizziness or feeling faint - Feeling of impending doom - Fever of 100.4°F (38°C) or higher - New or severe pain in your back or neck

Select Rare Side Effects

Side Effect	Talk to Your Care Team if You Have Any of These Signs or Symptoms
Cytomegalovirus (CMV) Reactivation	If you have had CMV in the past, receiving emapalumab could cause the virus to become active again. CMV reactivation may cause serious organ problems (for example, lung, liver, gut, or eye disease) and can be life threatening in people with weakened immune systems. Your care team will monitor you for CMV infection during treatment and for several months after treatment. - Fever or chills - New cough or shortness of breath - Severe stomach-are (abdominal) pain, diarrhea, or vomiting - Yellowing of skin or dark urine - New vision changes or eye pain - Unexplained severe tiredness or weakness

Before starting treatment, ask your care team when to call 9-1-1 or seek emergency help.
If you experience any new, worsening, or uncontrolled side effects, contact your care team immediately.

Intimacy, Pregnancy, and Breastfeeding

- Treatment may **change how you feel about intimacy and your body**. However, physical closeness—such as holding hands and hugging—remains safe. It is common to have questions about intimacy. If needed, talk to your care team for guidance.
- It is **not known** if emapalumab **may harm your unborn baby**. Talk to your care team about possible pregnancy and birth control choices that are right for you.
- It is **not known** if emapalumab is present in **breast milk**. Talk with your care team if you are breastfeeding or plan to breastfeed.

Additional Information

- **Tell your care team about all the medicines you take.**
This includes prescriptions, over-the-counter drugs, vitamins, and herbal products. Before starting any new medicine, supplement, or vaccine, ask your care team first.
- **You should not receive a “live vaccine”** before, during, or after treatment, until your care team tells you it is okay. If you are not sure about the type of immunization or vaccine, ask your care team. These vaccines may not be safe or may not work as well during treatment.
- **This Patient Education Sheet may not describe all possible side effects.**
Call your care team for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Notes

Updated Date: September 8, 2026

Scan the QR code below to access this education sheet.



Important Notice:

The Association of Cancer Care Centers (ACCC), Hematology/Oncology Pharmacy Association (HOPA), Network for Collaborative Oncology Development & Advancement, Inc. (NCODA), and Oncology Nursing Society (ONS) have collaborated to gather information and develop this patient education guide. This guide is a summary of the medication, based on information provided by the drug manufacturer and other sources.

This guide does not cover all information available on the possible uses, directions, doses, precautions, warnings, interactions, adverse effects, or risks associated with this medication. It should not be used as a substitute for the advice of a qualified healthcare professional. The provision of this guide is for informational purposes only. It does not constitute or imply endorsement, recommendation, or favoring of this medication by ACCC, HOPA, NCODA, or ONS, who assume no liability for and cannot ensure the accuracy of the information presented. All decisions regarding this medication should be made with the guidance and direction of a qualified healthcare professional.

Permission:

Patient Education Sheets are provided as a free educational resource for patients with cancer and their caregivers in need of concise, easy-to-understand information about cancer therapy. Healthcare providers may copy and distribute the sheets to patients and direct them to the Patient Education Sheets website. However, commercial reproduction or reuse, as well as rebranding or reposting of any type, are strictly prohibited without permission of the copyright holders. Permission requests, including direct linking from Electronic Health Records, and licensing inquiries should be emailed to patienteducationsheets@ncoda.org.

Copyright © 2026 by Network for Collaborative Oncology Development & Advancement, Inc. All rights reserved.

PES-675